1-3 of 3
Stephen K. Burley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SGX70393 Inhibits Bcr-Abl T315I In Vitro and In Vivo and Completely Suppresses Resistance When Combined with Nilotinib or Dasatinib.

Thomas O’Hare, Christopher A. Eide, Jeffrey W. Tyner, Amie S. Corbin, Matthew J. Wong, Sean Buchanan, Kevin Holme, Katayoun A. Jessen, Crystal Tang, Hal A. Lewis, Richard D. Romero, Stephen K. Burley, Michael W. Deininger
Journal: Blood
Blood (2007) 110 (11): 535.
https://doi.org/10.1182/blood.V110.11.535.535
Published: 2007
Journal Articles

Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.

Thomas O’Hare, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Matthew J. Wong, Caitlyn A. Smith, Amie S. Corbin, Sean Buchanan, PhD, Katayoun A. Jessen, PhD, Crystal Tang, Kevin Holme, PhD, Stephen K. Burley, MD, PhD, Michael W.N. Deininger, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1373.
https://doi.org/10.1182/blood.V108.11.1373.1373
Published: 2006
Journal Articles

Application of FAST TM Fragment-Based Lead Discovery and Structure-Guided Design to Discovery of Small Molecule Inhibitors of BCR-ABL Tyrosine Kinase Active Against the T315I Imatinib-Resistant Mutant.

Stephen K. Burley, MD, DPhil
Journal: Blood
Blood (2005) 106 (11): 698.
https://doi.org/10.1182/blood.V106.11.698.698
Published: 2005